As major multinational corporations (MNC) report their financial results for the second quarter of 2024, pharmaceutical industry leaders such as Astrazeneca, Roche, Sanofi, Johnson & Johnson and Novartis have announced their financial results for the first half of 2024 (H1). As of August 6, according to the operating income data of the first half of the year, the ranking of the top ten enterprises in the global pharmaceutical industry has been settled, and the specific ranking is as follows:
Quarterly and Half-Yearly Revenue and Year-Over-Year Growth Rate Chart for the Second Quarter and Full Year 2024
Rank
Company
2024 Q2 Revenue (Billion USD)
YoY Growth
2024 H1 Revenue (Billion USD)
YoY Growth
1
Johnson & Johnson
224.5
4.3%
438
3.3%
2
Roche
178.19
13.9%
337.19
5.0%
3
Merck
161.12
7.2%
318.87
8.0%
4
Pfizer
132
2.0%
281.62
-11.0%
5
AbbVie
144.62
4.3%
267.72
3.7%
6
AstraZeneca
129.38
13.3%
256.17
18.0%
7
Novartis
125.1
11.0%
243
11.0%
8
Bristol-Myers Squibb
122.01
9.0%
240.66
7.0%
9
Sanofi
117.22
10.2%
230.20
8.4%
10
GlaxoSmithKline
100.38
13.0%
194.12
12.0%
With the gradual fading of the novel coronavirus epidemic in 2023, the revenue pattern of the global large pharmaceutical companies has ushered in a new round of change. Entering 2024, the impact of the epidemic on business operations has significantly weakened, and pharmaceutical companies have gradually returned to the normal development track. From the performance point of view, in the first half of 2024, in addition to Pfizer, the revenue of the remaining nine pharmaceutical companies generally showed an increase.
Against this backdrop, Johnson & Johnson has solidified its position as the top global pharmaceutical and medical device company in terms of revenue. According to the financial data for the first half of 2024, Johnson & Johnson's overall revenue reached $43.83 billion, an increase of 3.3%. From the perspective of treatment segment segmentation, the tumor segment is particularly strong, and its revenue has surpassed the autoimmune diseases segment to become the largest revenue contribution of Johnson & Johnson. Specifically, revenue from the oncology segment reached $5.09 billion in the second quarter, up 15.7% year over year; In the autoimmune diseases segment, revenue in the same period was $4.722 billion, a growth rate of only 5%.
In terms of product lines, Darzalex in oncology, with its $5.57 billion in sales, successfully surpassed Stelara in autoimmune diseases ($5.536 billion in sales) to become the top-selling product in the first half of 2024. In addition, two new oncology drugs, BCMA CAR-T therapy Carvykti and dual antibody product Tecvayli, also showed strong growth momentum, with sales reaching $343 million and $268 million, respectively, with year-on-year growth rates of 81.5% and 70.2%.
In order to further strengthen its competitiveness in the field of oncology and immunization, Johnson & Johnson continues to increase investment in innovative drugs. In the first half of 2024, J&J completed a number of important acquisitions. Among them, the $2 billion acquisition of AmbrxBiopharma brought several ADC pipelines to the company; The $850 million acquisition of Proteologix and the $1.25 billion acquisition of a subsidiary of NumabTherapeutics further strengthen the company's portfolio of dual antibody products in the field of autoimmune diseases.
Roche showed solid growth in the first half of 2024, with total revenues of CHF 29.848 billion (US $33.719 billion), up 5% year-on-year. Among them, the pharmaceutical business, as the core driver, contributed 22.637 billion Swiss francs (about $25.573 billion) in revenue, and China revenue achieved double-digit growth to reach 1.609 billion Swiss francs (about $1.818 billion).
In pharmaceuticals, the oncology segment continued to play a leading role, contributing 9.619 billion Swiss francs ($10.867 billion), or 42.5% of total revenue, to Roche, which remained at 4% despite a slight slowdown in year-on-year growth. In contrast, the ophthalmology business showed strong growth with revenues of CHF 1.891 billion, up 54% year on year, and although it currently accounts for only 8.4% of total revenues, its potential cannot be ignored.
Specific to the product level, the ophthalmological double antibody Vabysmo (Pharisimumab) performance is particularly outstanding, the first half of the sales revenue of up to 1.794 billion Swiss francs (about 2.027 billion US dollars), an increase of 93%, almost doubled, successfully ranked among Roche's top 5 best-selling drugs. In addition, Ocrevus (Orizumab), Hemlibra (Emetzizumab), Evrysdi (Rispran), Phesgo (Trastuzumab + pertuzumab), Polivy (Vipostuzumab), Xolair (Omazumab), Alecensa (Aletinib) and other drugs also remained strong Growth trend.
On the other hand, Merck also achieved impressive results in the first half of 2024. The company's total revenue reached $31.887 billion, an increase of 8%, and pharmaceutical revenue reached $28.415 billion, an increase of 9%. Revenue in the second quarter was $16.1 billion, up 7 percent from a year earlier. This increase was mainly due to the excellent performance of K-drug (Pabolizumab) and HPV vaccine.
As a star product of Merck, K drug sales reached 14.217 billion US dollars in the first half of this year, achieving a double-digit high growth of 18%, and is expected to break through the 30 billion US dollars mark for the whole year. At the same time, HPV vaccines also maintained a stable sales performance, Gardasil/Gardasil 9 sales reached $4.727 billion, an increase of 7%.
In addition, the company's oncology products such as Welireg (HIF-2α inhibitor) and Reblozyl (Rottsip), as well as the anti-cytomegalovirus infection drug Prevymis (Lytamovir) and 15-valent pneumococcal vaccine Vaxneuvance, also achieved double-digit or higher growth.
However, it is worth noting that Merck's main revenue is still highly dependent on K drugs and HPV vaccines. Among them, K drug sales accounted for nearly half of the company's total revenue. Although K-drug is still in a period of rapid growth, its patent will expire in 2028, when it will face the risk of declining sales. At the same time, the HPV vaccine market is increasingly competitive, and Merck's HPV vaccine sector revenue is not indestructible.
As a result, MSD is actively pursuing a second growth curve. Since the beginning of this year, the company has continuously introduced new potential products and pipelines through acquisitions, including pneumonia conjugate vaccine, the new drug Sotatercept for pulmonary hypertension, a new generation of RSV neutralizing antibodies, TL1A antibodies, and neoantigen mRNA vaccines, with a view to achieving more diversified revenue sources in the future.
Among the world's top 10 multinational pharmaceutical companies, Pfizer has been the most affected by the COVID-19 pandemic. In 2023, due to the sharp decline in sales of new coronavirus vaccine Comirnaty and anti-new coronavirus drug Paxlovid, the company failed to continue the brilliant performance of over 100 billion dollars in 2022, not only lost the top position in the industry, but also withdrew from the top three ranks. Entering 2024, although the first half of the revenue decline is still as high as 11%, showing that the company has not completely rid of the negative impact of the fading of the new coronavirus dividend, but the second quarter performance has shown signs of recovery. Financial data show that in the first half of 2024, the company's total revenue was 28.162 billion US dollars, down 11% year-on-year; In the second quarter, revenue reached $13.2 billion, up 2% from the same period last year and exceeding market analysts' expectations ($12.96 billion). If the contribution of COVID-19 vaccines and oral COVID-19 drugs is not included, the revenue growth in the second quarter was more significant, reaching 14%, which is the first time since the global coronavirus epidemic gradually eased in the fourth quarter of 2022, Pfizer achieved positive quarterly revenue growth, marking the company has adjusted to a good state and embarked on a new journey.
From the perspective of business structure, in the first half of 2024, the revenue of COVID-19 product Paxlovid was 2.286 billion US dollars, down 46% year-on-year; Comirnaty's revenue was $548 million, down 88% year over year. Despite the continued decline in revenue from COVID-19 products, the company's oncology business has achieved rapid growth, reaching $7.505 billion in revenue in the first half of the year, up 23% year-on-year. Among them, the breast cancer blockbuster CDK4/6 inhibitor Ibrance (Pipercilil), despite a slight decline in sales (-8%), still topped oncology drug sales with $2.184 billion in revenue. Androgen receptor signaling inhibitor Xtandi (Enzaluamide) and third-generation ALK inhibitor Lorbrena (Loratinib) also saw growth of 20% and 46%, respectively, with revenues of $913 million and $332 million, respectively.
In addition, ADCs such as Vyndaqel (chlorobenzolic acid), Eliquis (Apoxaban) and Nurtec ODT/Vydura, which were acquired through the Seagen acquisition, also began to contribute to the company's revenue.
Abbvie also showed solid growth in the first half of 2024, with total revenue of $26.772 billion, up 3.7% year-on-year. In terms of therapeutic areas, autoimmune diseases, neuroscience, and oncology were the three pillars of the company's revenue, generating $12.342 billion (+0.6%), $4.127 billion (+15.6%), and $3.177 billion (+11%), respectively.
In the autoimmune diseases segment, although Humira (Adalimumab) has failed to reverse the downward trend in performance, with a decline of about 32% to $5.084 billion, full-year revenue is expected to fall below the $10 billion mark. However, the company's two star products in the field, Skyrizi (Lisencizumab) and Rinvoq (Upatinib), have maintained strong growth momentum, achieving revenue of $4.735 billion (+46.6%) and $2.523 billion (+60.4%), respectively, of which Skyrizi is expected to break the $10 billion revenue mark by the end of the year.
In the oncology segment, Imbruvica continued to lose market share, with first-half revenue down 6.4% year-on-year to $1.671 billion; Venclexta, on the other hand, maintained steady growth, with first-half sales of $1.251 billion (+16%). In addition, the new blood cancer product CD3/CD20 dual antibody Epkinly since the FDA approved the market in May last year, sales have also doubled, from $31 million in the first half of 2023 to $63 million in the first half of this year. At the same time, the FRα ADC drug Elahere (Somituximab) acquired by the company in the acquisition of ImmunoGen late last year also contributed $192 million to the company's revenue in six months.
In the neuroscience segment, with the exception of Duodopa, a drug for Parkinson's disease, which showed negative growth, all products achieved steady growth. Although Qulipta's sales volume is not large ($281 million in revenue in the first half of the year), the growth rate is as high as 73.2%, becoming the fastest growing product in the field. Other products such as Ubrelvy, Botox Therapeutics and Vraylar also saw varying degrees of growth. Looking ahead, as AbbVie's pipeline in neuroscience continues to advance and its layout is optimized, the company is expected to continue to expand its market advantage in this field.
Novartis continues to deepen its commitment to nuclear medicine and invests in small nucleic acids and gene therapy. In the first half of 2024, Novartis achieved total revenue of $24.3 billion, an increase of 11%, of which sales in the China market reached $2.1 billion, an increase of 29%.
In the therapeutics segment, Novartis is showing strong growth. Oncology revenue reached $6.984 billion, up 14% year-over-year; Cardiovascular/renal metabolism revenue of $4.111 billion, up 37% year-over-year; Immunization revenue was $4.403 billion, up 21% year on year; Revenue in the neuroscience segment was $2.234 billion, up 39% from a year earlier.
Within these areas, several of Novartis's core products performed well, such as Entresto (sacubactril valsartan) revenue of $3.777 billion, up 30% year-over-year; Kesimpta (Oftolumab) revenue of $1.436 billion, an increase of 64%; Cosentyx revenue of $2.852 billion, up 21% year-over-year; Kisqali (Ribosili) revenue of $1.344 billion, an increase of 48%.
In addition, Novartis's layout in the field of nuclear drugs has also achieved significant results. In the first half of the year, Pluvicto and Lutathera generated revenue of $655 million (+45%) and $344 million (+16%), respectively, for a combined revenue of nearly $1 billion. Meanwhile, sales of Leqvio, a long-acting PCSK9 siRNA lipd-lowering drug, reached $333 million, up 135% year-over-year, making it Novartis' fastest growing new drug category. Gene therapy products also performed well, with Zolgensma, which treats spinal muscular atrophy (SMA), reporting first-half revenue of $644 million, up 6 percent year-on-year.
It is worth noting that Novartis has shown a unique vision in product development and M&A strategy. Unlike other multinational pharmaceutical companies (MNC), Novartis's products and research pipeline are less involved in ADC, PD-1, GLP-1 and other hot tracks. Instead, Novartis prefers to focus on the development of cutting-edge technologies and innovative therapies, such as nuclear drugs, small nucleic acids, cell and gene therapies (CGT). Although the combined revenue of these emerging areas is still less than 10% of total revenue, Novartis's future development prospects will be broader as the market matures in the future.
In addition, the top 10 MNCS such as Astrazeneca, Sanofi, GlaxoSmithKline, Bristol-Myers Squibb also achieved positive revenue growth in the first half of 2024. With the intensification of market competition, each MNC is actively adjusting its strategy, some grasp the hot spots of The Times to expand the advantages of the field, some choose to avoid homogenized competition, and some focus on the core business by cutting off non-core assets. All these efforts are in order to stand out in the fierce market competition, looking forward to the second half of the MNC can continue to bring wonderful performance.